Pharma & Obesity
Eli Lilly obesity pill sees early prescription uptake
What's happening
Eli Lilly's newly launched oral obesity drug, Foundayo™ (orforglipron), recorded 3,707 prescriptions in its second week in the U.S., signaling early adoption. This follows an initial 1,390 prescriptions in its debut week, as the pill begins its rollout through LillyDirect and retail pharmacies.
What's changing / Business impact
-
Oral GLP-1 alternatives may: improve patient convenience and expand the addressable market for those averse to needles.
-
Strong early uptake indicates: high unmet demand and rapid adoption potential for non-injectable options.
-
Intensifies competition: Lilly is now battling for market share against Novo Nordisk's oral Wegovy in the highly competitive obesity drug segment.
Why this matters
Drug format (pill vs injection) can significantly influence patient behavior and adoption.
This shows:
-
Convenience is becoming a key competitive factor as the "first-gen" injectable market saturates.
-
Innovation is shifting from just efficacy → delivery experience and lifestyle integration.
-
Demand in obesity treatment remains extremely strong and elastic despite the influx of new treatment types.